1 湖南省儿童医院呼吸一科，长沙 410000
|| 湖南省科技厅临床医疗技术创新引导项目 (2017SK50705)。
Clinical features and changes of lymphocyte subsets of 95 pediatric patients with pertussis-like syndrome
This work was supported by the Clinical Medical Technology Innovation Guidance Project of Hunan Science and Technology Department, China (2017SK50705).
Objective: To explore the clinical features and changes of lymphocyte subsets in 95 pediatric patients with pertussis-like syndrome. Methods: The clinical features and changes of lymphocyte subsets before and after macrolide treatment were retrospectively analyzed among 95 pediatric patients with pertussis-like syndrome who were admitted to the Department of Respiratory Medicine of Hunan Children’ s Hospital from January 2017 to January 2018. The t test was used for statistical analysis. Results: 1) A total of 95 hospitalized pediatric patients with pertussis-like syndrome were enrolled, and there were 46 (48.40%) females and 49 (51.60%) males. Among them, there were 64 cases (67.37%) aged ≤3 months without history of pertussis vaccination, 31 cases (32.63%) aged >3 months with history of pertussis vaccination. 2) There were 60 cases (63.16%) negative for respiratory virus antigen, 35 cases (36.84%) positive for respiratory virus antigen; 61 cases (64.21%) negative and 34 cases (35.79%) positive for sputum culture; 78 cases (82.10%) negative and 17 cases (17.90%) positive for Mycoplasma pneumoniae or Chlamydia pneumoniae. 3) Among patients aged ≤3 months, the average CD3 values were 50.00 and 56.12 before and after macrolide treatment respectively, the difference was statistically significant (P<0.05); for CD4, the average values were 24.33 and 28.64 before and after macrolide treatment respectively with statistically significant difference (P<0.05). No statistically significant differences were found in the average values of CD8 and CD4/CD8 before and after macrolide treatment. Among patients aged >3 months, there were no significant differences in the average values of CD3, CD4, CD8 and CD4/CD8 before and after macrolide treatment. Conclusion: Most pediatric patients with pertussis-like syndrome are aged ≤3 months without history of pertussis vaccination. The lymphocyte subsets in this group have changes before and after macrolide treatment. For these patients, macrolides given as early as possible in clinical practice may be beneficial to disease recovery.
pertussis-like syndrome; lymphocyte subsets; macrolides